Publication:


abstract

We characterized the initiation and evolution of the immune response against a new inducible p53-dependent model of aggressive Ovarian carcinoma that recapitulates the leukocyte infiltrates and cytokine milieu of advanced human tumors. Unlike other models that initiate tumors before the development of a mature immune system, we detect measurable anti-tumor immunity from very early stages, which is driven by infiltrating dendritic cells (DCs) and prevents steady tumor growth for prolonged periods. Coinciding with a phenotypic switch in expanding DC infiltrates, tumors aggressively progress to terminal disease in a comparatively short time. Notably, tumor cells remain immunogenic at advanced stages, but anti-tumor T cells become less responsive, whereas their enduring activity is abrogated by different microenvironmental immunosuppressive DCs. Correspondingly, depleting DCs early in the disease course accelerates tumor expansion, but DC depletion at advanced stages significantly delays aggressive malignant progression. Our results indicate that phenotypically divergent DCs drive both immunosurveillance and accelerated malignant growth. We provide experimental support for the cancer immunoediting hypothesis, but we also show that aggressive cancer progression after a comparatively long latency period is primarily driven by the mobilization of immunosuppressive microenvironmental leukocytes, rather than loss of tumor immunogenicity.

Related Articles
CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.
J Immunol. 2010
CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.
Nesbeth YC, Martinez DG, Toraya S, Scarlett UK, Cubillos-Ruiz JR, Rutkowski MR, Conejo-Garcia JR. J Immunol. 2010 May 15; 184(10):5654-62. Epub 2010 Apr 16.
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.
Cancer Res. 2008
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.
Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ, Benencia F, Stan RV, Keler T, Sarobe P, et al. Cancer Res. 2008 Sep 15; 68(18):7684-91. Epub 2008 Sep 3.
Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer.
J Immunol. 2011
Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer.
Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL. J Immunol. 2011 Jun 15; 186(12):6905-13. Epub 2011 May 6.
Review Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes.
Cell Cycle. 2010
Review Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes.
Cubillos-Ruiz JR, Rutkowski M, Conejo-Garcia JR. Cell Cycle. 2010 Jan 15; 9(2):260-8. Epub 2010 Jan 26.
Review Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.
Int J Gynecol Pathol. 2008
Review Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.
Kurman RJ, Shih IeM. Int J Gynecol Pathol. 2008 Apr; 27(2):151-60.